European Medecine Agency (EMA) review of Finasteride and Dutasteride
    Finasteride/Dutasteride 10/6/2024

    From the encyclopedia
    Finasteride →

    Popular 5-alpha reductase inhibitor that lowers DHT, taken as a pill or used topically

    Dutasteride →

    5-alpha reductase inhibitor that blocks both enzyme types, a stronger DHT blocker than finasteride

    Pyrilutamide →

    Experimental topical anti-androgen, also known as KX-826

    At a glance
    In this general discussion post, the primary subjects mentioned are the tone is 😞 negative.

    Other terms

    Concerns about a potential ban on finasteride and dutasteride due to side effects, with users advocating for continued access and informed choice. Alternative treatments like pyrilutamide are also mentioned.
    View this post in the Community →

    Similar Community Posts Join

    6 / 6 results

    Related Research

    6 / 6 results

      research The 100 most cited articles in androgenetic alopecia: A bibliometric analysis

      March 2025 in “Medicine”
      This study performed a bibliometric analysis of the 100 most cited articles on androgenetic alopecia from 1975 to 2024, revealing that U.S. authors contributed most and highlighting a trend toward research focused on treatment options, especially between 2020 and 2024.

      research The Hormonal Background of Hair Loss in Non-Scarring Alopecias

      February 2024 in “Biomedicines”
      This review examines the hormonal causes of hair loss, noting how androgen excess can lead to follicle miniaturization and linking estrogen deficiency and thyroid dysfunction to common alopecia types. It further discusses hormonal treatments such as finasteride, dutasteride, and spironolactone.

      research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique

      March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)”
      This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.

      research Androgenetic Alopecia: Therapy Update

      May 2023 in “Drugs”
      This comprehensive review analyzes androgenetic alopecia treatments, discussing the mechanisms, costs, efficacy, and safety of FDA-approved drugs like minoxidil and finasteride, as well as newer non-FDA-approved options that have shown effectiveness across various studies.